The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease

Kidney International, Supplement

Volumn 64, Issue 87, 2003, Pages

  Block, Geoffrey A ^a,b  

^a Denver Nephrologists   (United States)

^b NONE   (United States)

Author keywords

AMG 073; Calcimimetics; Cinacalcet HCl; Secondary hyperparathyroidism; Vascular calcification

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CALCIUM SENSING RECEPTOR; CINACALCET; N [3 (2 CHLOROPHENYL)PROPYL] 1 (3 METHOXYPHENYL)ETHYLAMINE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; STEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D; POLYAMINE; POLYCATIONS;

ABDOMINAL PAIN; ADYNAMIC BONE; BLOOD VESSEL CALCIFICATION; BONE DISEASE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY FAILURE; MINERAL METABOLISM; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PARATHYROID HORMONE RELEASE; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VOMITING; BONE; BONE DENSITY; CHRONIC KIDNEY FAILURE; DRUG POTENTIATION; METABOLISM; RENAL OSTEODYSTROPHY;

BONE AND BONES; BONE DENSITY; CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; POLYAMINES; RENAL OSTEODYSTROPHY; VITAMIN D;

EID: 0142169488     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.64.s87.20.x     Document Type: Review

References (39)

1. BROWN EM, GAMBA G, RICCARDI D, et al: Cloning and characterization of an extra-cellular Ca++ sensing receptor from bovine parathyroid. Nature 366:575-580, 1993
2. LINDBERGH J, MOE SM, GOODMAN WG, et al: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63:248-254, 2003
3. CORESH J, ASTOR BC, GREENE T, et al: Prevalence of chronic kidney disease and decreased kidney function in the adult U.S. population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41(1):1-12, 2003
4. MARTINEZ I, SARACHO R, MONTENEGRO J, LLACH F: The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29(4):496-502, 1997
5. HSU C-Y, CHERTOW GM: Elevations in serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 17(8):1419-1425, 2002
6. KAUSZ AT, KHAN SS, ABICHANDANI R, et al: Management of patients with chronic renal insufficiency in the northeastern United States. JASN 12:1501-1507, 2001
7. TAKAHASHI F, DENDA M, FINCH JL, et al: Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int 61:1332-1338, 2002
8. SLATOPOLSKY E: The role of calcium, phosphorus, and vitamin D metabolism in the development of secondary hyperparathyroidism. Nephrol Dial Transplant 13(Suppl 3):3-8, 1998
9. SLATOPOLSKY E, FINCH J, DENDA M: Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 97:2534-2540, 1996
10. NEMETH EF: Pharmacologic regulation of parathyroid hormone secretion. Curr Pharm Des 8:2077-2087, 2002
11. PEARCE SHS: Clinical disorders of extracellular calcium sensing and the molecular biology of the calcium sensing receptor. Ann Med (34)201, 2002
12. NEMETH EF, STEFFEY ME, HAMMERLAND LG: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045, 1998
13. FRAZAO JM, MARTINS P, COBURN JW: The calcimimetic agents: perspectives for treatment. Kidney Int 61(Suppl 80):S149-S154, 2002
14. YALCINDAG C, SILVER J, NAVEH-MANY T: Mechanism of increased parathyroid hormone mRNA in experimental uremia: Roles of protein RNA binding and RNA degradataion. JASN 10:2562-2568, 1999
15. LI YC, AMLING M, PIRRO AE, et al: Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets and osteomalacia, but not alopecia in vitamin D receptor ablated mice. Endocrinology 139:4391-4396, 1998
16. GARNER SC, PI M, TU Q, QUARLES LD: Rickets in cation sensing receptor deficient mice: An unexpected skeletal phenotype. Endocrinology 142(9):3996-4005, 2001
17. WADA M, NAGANO N, FURUYA Y, et al: Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50-58, 2000
18. WADA M, ISHII H, FURUYA Y: NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 53:448-453, 1998
19. WADA M, FURUYA Y, SAKIYAMA J: The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977-2983, 1997
20. AMANN K, RITZ E, WIEST G, et al: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. JASN 4:1814-1819, 1994
21. AMANN K, TORNIG J, FLECHTENMACHER C, et al: Blood pressure independent wall thickening of intramyocardial arterioles in experimental uremia: Evidence for a permissive actin of PTH. Nephrol Dial Transplant 10:2043-2048, 1995
22. OGATA H, RITZ E, ODONI G, et al: Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. JASN 14:959-967, 2003
23. AMANN K, TORNIG J, KUGEL B, et al: Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experiemental uremia. Kidney Int 63:1296-1301, 2003
24. MALBERTI F, MARCELLI D, CONTE F: Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. J Am Soc Nephrol 12:1242-1248, 2001
25. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO4, CaxPO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. JASN 12:2131-2138, 2001
26. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, PORT FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31(4):607-617, 1998
27. KLASSEN PS, LOWRIE EG, REDDAN DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287(12):1548-1555, 2002
28. TAAL MW, ROE S, MASUD T, et al: Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63:1116-1120, 2003
29. JONO S, MCKEE MD, MURRY CE, et al: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:10-17, 2000
30. MOE SM, DUAN D, DOEHLE BP, et al: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63:1003-1011, 2003
31. LONDON GM, MARCHAIS SJ, GUERIN AP, et al: Arterial structure and function in end stage renal disease. Nephrol Dial Transplant 17:1713-1724, 2002
32. GUERIN AP, LONDON GM, MARCHAIS SJ, METIVIER F: Arterial stiffening and vascular calcifications in end stage renal disease. Nephrol Dial Transplant (15):1014-1021, 2000
33. GUERIN AP, BLACHER J, PANNIER B, et al: Impact of aortic stiffness attenuation on survival of patients in end stage renal failure. Circ 103:987-992, 2001
34. LONDON GM, MARCHAIS SJ, SAFAR ME, et al: Aortic and large artery compliance in end stage renal failure. Kidney Int 37:137-142, 1990
35. BLACHER J, GUERIN AP, PANNIER B, et al: Impact of aortic stiffness on survival in end stage renal disease. Circ 99:2434-2439, 1999
36. CHERTOW GM, BURKE SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
37. GOODMAN WG, FRAZAO JM, TURNER SA: Use of a calcimimetic agent to lower plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Kidney Int 58:436-445, 2000
38. NEMETH EF, BENNETT SA: Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transplant 13:1923-1925, 1998
39. NEER RM, ARNAUD CD, ZANCHETTA JR: Effect of parathyroid hormone (1-34) on fractures and bone mineral denisty in postmenopausal women with osteoporosis. New Engl J Med 344(1434): 1441, 2001